Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $3.7199, but opened at $3.90. Curaleaf shares last traded at $3.53, with a volume of 426,983 shares changing hands.
Analyst Ratings Changes
CURLF has been the topic of several recent analyst reports. Canaccord Genuity Group raised Curaleaf to a "strong-buy" rating in a research report on Thursday, October 9th. ATB Capital raised Curaleaf to an "outperform" rating in a report on Tuesday, December 2nd. Finally, Atb Cap Markets raised Curaleaf from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, December 2nd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Strong Buy".
View Our Latest Research Report on CURLF
Curaleaf Stock Performance
The firm has a market cap of $2.48 billion, a PE ratio of -11.44 and a beta of 0.77. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71. The stock has a 50-day moving average price of $2.70 and a 200 day moving average price of $2.13.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. Research analysts forecast that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.